San Diego, CA — Binding Site’s Immunologicals Group is pleased to announce the addition of three (3) new Bordetella pertussis (VZV) antigens to its broad offering of products for in-vitro diagnostic (IVD) manufacturing and research applications. The Bordetella pertussis FHA; Bordetella pertussis Toxin PT; and Bordetella pertussis Whole-Cell Antigens have been expressly designed for use as integral components within solid phase enzyme immunoassay test procedures. As such, the availability of these antigens will benefit the needs of life science, biopharmaceutical, clinical, and drug-discovery researchers, as well as manufacturers of IVD test kits.
In the USA alone, almost 20,000 people died each year before a vaccine was made available. Bordetella pertussis is the causative agent of Pertussis, or “Whooping Cough”. In addition, Bordetella pertussis also has the ability to inhibit the function of the host's immune system via pertussis toxin (PT). This targets phagocytes to convert too much ATP into cyclic AMP, which can cause disturbances in cellular signaling mechanisms, and prevents phagocytes from correctly responding to an on-going infection.
All of these Bordetella pertussis antigens exhibit exceptional purity levels as a result of chromatography techniques and demonstrate exceptional lot-to-lot consistencies, while displaying the highest degrees of activity and specificity. They all feature an outstanding shelf life stability claim of 10 years from the date of manufacture and are offered in a standard sized 1.0mg filled vial, with larger, bulk configurations also being available.
Binding Site’s Immunologicals Group serves the in-vitro diagnostic (IVD) manufacturing and biopharmaceutical | clinical | life-science | medical research markets with a comprehensive line of innovative products. For additional information, contact The Binding Site, Inc. at 6730 Mesa Ridge Road, San Diego, CA 92121 USA. Phone: 800-633-4484; FAX: 858-453-9189; Email: email@example.com. Please visit our website at www.immunologicals.com.